Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$110.94 USD
+1.05 (0.96%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $110.95 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$110.94 USD
+1.05 (0.96%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $110.95 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
Zacks News
Here's Why You Should Retain Align Technology (ALGN) Stock Now
by Zacks Equity Research
Investors are optimistic about Align Technology (ALGN), led by its strong global presence.
Zimmer Biomet (ZBH) Q3 Earnings Top Estimates, Margins Fall
by Zacks Equity Research
Zimmer Biomet (ZBH) gains from solid strategic execution and increasing traction in innovations in the third quarter.
OPKO Health (OPK) Q3 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall third-quarter results reflect soft performances.
Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Loss in Q3
by Zacks Equity Research
Myriad Genetics' (MYGN) third-quarter 2023 revenues increase year over year, driven by strong testing volume improvement across all its businesses.
Shockwave Medical (SWAV) Q3 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Shockwave Medical's (SWAV) third-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launches.
Insulet (PODD) Q3 Earnings Beat, 2023 Sales Growth View Up
by Zacks Equity Research
Insulet's (PODD) third-quarter 2023 revenues increase year over year as a result of continued high demand for Omnipod 5.
Inari Medical (NARI) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Inari Medical's (NARI) third-quarter results benefit from strong product adoption and geographical performances.
AMN Healthcare (AMN) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
AMN Healthcare's (AMN) dismal results in all its segments led to a soft overall third-quarter performance.
Cardinal Health (CAH) Beats on Q1 Earnings, Ups '24 EPS View
by Zacks Equity Research
Cardinal Health's (CAH) first-quarter fiscal 2024 results benefit from the Pharmaceutical segment's solid performance.
Stryker (SYK) Q3 Earnings Beat on Strong Segmental Result
by Zacks Equity Research
Stryker's (SYK) third-quarter earnings reflect strong performance across its segments and geographies. However, unfavorable currency movement hurts sales growth, and rising costs affect margins.
Fresenius Medical (FMS) Q3 Earnings Miss, Operating Margin Up
by Zacks Equity Research
Fresenius Medical's (FMS) third-quarter revenues suffer due to unfavorable currency movement. However, the company's transformational plans continue to benefit its operating income.
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
Penumbra (PEN) Q3 Earnings Top Estimates, Margins Increase
by Zacks Equity Research
Penumbra's (PEN) vascular and neuro product categories continue to show encouraging growth trends.
Avanos (AVNS) Q3 Earnings Top Estimates, Margins Contract
by Zacks Equity Research
Despite strength in Avanos' (AVNS) Digestive Health segment, its overall third-quarter results reflect soft performances.
QuidelOrtho (QDEL) Q3 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Despite solid performances by the Labs and TM segments and China and Other regions, QuidelOrtho (QDEL) reports soft overall top-line results in third-quarter 2023.
Nevro (NVRO) Q3 Earnings Top Estimates, FY23 Revenue View Up
by Zacks Equity Research
Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in the third quarter, owing to robust domestic performance.
Cencora (COR) Q4 Earnings Top, GLP-1 Drugs Boost Sales
by Zacks Equity Research
Cencora's (COR) fourth-quarter fiscal 2023 results benefit from overall market growth, including rising demand for GLP-1 drugs approved for diabetes and weight loss. Inflationary pressure remains.
Exact Sciences (EXAS) Q3 Earnings Beat, Gross Margin Rises
by Zacks Equity Research
Exact Sciences' (EXAS) Screening revenue upside is primarily attributable to broad-based momentum in Cologuard adoption.
Baxter (BAX) Beats on Q3 Earnings, Divests BioPharma Business
by Zacks Equity Research
Baxter (BAX) reports better-than-expected third-quarter earnings and sales. The company completes the divestment of its BioPharma Solution business. It starts reporting under a new operating model.
DENTSPLY SIRONA (XRAY) Beats on Q3 Earnings, Lowers '23 Guidance
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) Q3 revenues are driven by a rise in demand for aligners and CAD/CAM in the United States and a recovery in demand in China. Challenging macro headwinds linger.
Glaukos (GKOS) Q3 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Glaukos' (GKOS) third-quarter revenues beat estimates but fall year over year. Sales and gross margin improve, while higher operating expenses lead to a wider operating loss.
McKesson (MCK) Beats on Q2 Earnings, Raises '23 EPS View
by Zacks Equity Research
McKesson's (MCK) second-quarter fiscal 2024 results benefit from growth in the United States. Divestment hurts the International segment.
CVS Health (CVS) Q3 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Robust sales growth across all three operating segments drove CVS Health's (CVS) third-quarter results.
PacBio (PACB) Tops on Q3 Earnings, Raises FY23 Revenue View
by Zacks Equity Research
PacBio (PACB) witnesses strong revenue growth in the third quarter, partly aided by customers' continued product transition to the Revio system.
Ecolab (ECL) Q3 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Ecolab's (ECL) robust performance across all segments drives its third-quarter sales despite business challenges.